Global Growth USA Immuno-Oncology 2017-18

Important results from the project

The objective of the event was to expand and strengthen our immuno-oncology network in order to establish partnerships leading to long-term growth of the company. Several meetings with pharma and biotech companies as well as key opinion leaders in immuno-oncology were held. Further discussions with all types of stakeholders are currently ongoing, exploring future out-licensing of Alligator´s drug candidates, co-development/in-licensing from biotech companies to expand Alligator´s project portfolio as well as collaboration with clinical and pre-clinical scientists.

Expected long term effects

During the event, we met several potential partners and were able to follow up previous interactions as well as establish novel contacts. Several discussions resulted in a mutual interest in exploring a potential partnership further. In the short term, the ongoing discussions are expected to contribute to a successful out-licensing of one of Alligator´s drug candidates, as well as further strengthening the company´s project portfolio by partnership with biotech and academia. In the long term, this is expected to result in increased growth and profitability of the company.

Approach and implementation

Meetings and seminars were held with various players in the field of immuno-oncology in Boston, New York and Bethesda. A major part of the program was pre-arranged, but there was sufficient room for participants to make their own arrangements. Combining pre-booked meetings with pharma companies, open seminars and mingling events was successful. It enabled meetings with prioritized contacts as well as unexpected interactions, which was very productive.